Please login to the form below

Not currently logged in
Email:
Password:

Senior hire for 3D Communications

Allison May Rosen joins as communications lead for FDA Advisory Committee projects
3D Communications Allison May Rosen

Consultancy firm 3D Communications has named Allison May Rosen as communications lead for its projects related to the US Food and Drug Administration's (FDA) advisory committee.

Rosen, a Washington DC-based healthcare communications strategist and trainer, joins from Chandler Chicco, where she ran the DC office and led public health and healthcare programmes.

Bringing more than two decades' experience in both the public and private sectors, Rosen will working with clients 'to synthesize their science' for FDA audiences, the agency said. She will also conduct speaker and media training for clients.

3D Communications founding partner Cindy DiBiasi said she was very excited to have Rosen join.

“Allison May Rosen's years of experience on the front lines of Washington DC health policy, combined with her knowledge of complex health care issues and her communications skills, are a terrific addition to 3D's team of scientific and communications experts,” she added.

Rosen began her career working for Governor Ann Richards at the Texas Office of State-Federal Relations. She has served as vice president for public affairs at the Association for Competitive Technology and as press secretary for the federal government's Overseas Private Investment Corporation.

“Joining the 3D team is a huge honour and a platform for doing truly great things,” she said.

12th December 2013

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....